A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether canakinumab in combination with
chemoradiation and durvalumab is an effective and safe treatment for people with locally
advanced non-small cell lung cancer (NSCLC).